Compare Vertex Pharmaceuticals Incorporated (VRTX) vs Financial Select Sector SPDR Fund (XLF) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Vertex Pharmaceuticals Incorporated vs Financial Select Sector SPDR Fund — how do they compare? Vertex Pharmaceuticals Incorporated trades at $522.29 (market cap $134.06B), while Financial Select Sector SPDR Fund trades at $57.29. Which is the better fit depends on your goals.
| VRTX | XLF | |
|---|---|---|
Market Cap | $134.06B | — |
Sector | Health | — |
52-Week High | $557.96 | $58.55 |
52-Week Low | $376.62 | $47.80 |
Enterprise Value | $128.18B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Vertex Pharmaceuticals (VRTX) trades at $528.9, down 3.15% on the day, amid a mixed technical and fundamental backdrop. The stock shows a bullish moving average signal but neutral oscillators, with key support at $522. Fundamentally, 2025 revenue reached $12.0B with a strong net income margin of 35%, though recent quarterly EPS results have been mixed. The company recently completed the acquisition of Crinetics Pharmaceuticals, signaling growth ambitions.
The outlook remains positive given analyst consensus favoring a Buy rating (84%) and a $548.78 price target, implying upside. Key opportunities include revenue growth from new drug launches, while risks involve competitive pressures and earnings volatility. The stock's current valuation at a P/E of 30.8 requires sustained execution to justify further gains.
XLF, the Financial Select Sector SPDR Fund, trades at $57.3, down 1.38% over 24 hours. The technical outlook is neutral overall, with bullish moving averages but neutral oscillators, and key support at $57. Recent news highlights consolidation amid shifting interest rate expectations and fund manager rotation into financials in Q2 2026. The ETF offers exposure to 76 large-cap U.S. financial firms with a low expense ratio of 0.08%.
The outlook for XLF is balanced. Potential upside exists from rising interest rates benefiting banks and institutional inflows, but risks include economic sensitivity and sector volatility. The neutral technical and sentiment signals suggest a wait-and-see approach, with the dividend providing modest income.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio for cystic fibrosis, where Vertex therapies remain the standard of care globally. In addition to its focus on cystic fibrosis, Vertex is diversifying its pipeline through gene-editing therapies such as CTX001 for beta-thalassemia and sickle-cell disease, small-molecule inhibitors targeting acute and chronic pain using non-opioid treatments, and small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.
Read more on VRTX →About Financial Select Sector SPDR Fund
The fund generally invests substantially all, but at least 95%, of its total assets in the securities comprising the index. The index includes securities of companies from the following industries: diversified financial services; insurance; banks; capital markets; mortgage real estate investment trusts; consumer finance; thrifts; and mortgage finance. The fund is non-diversified.
Read more on XLF →
